New COVID Vaccine for Clinical Trials Approved

China's Sinopharm COVID-19 vaccine has recently been approved for clinical trials. The vaccine is based on the structural features of the receptor binding domain (RBD) on the virus' spike protein (S-protein).

China's Sinopharm COVID-19 vaccine has recently been approved for clinical trials.

The new recombinant Covid-19 vaccine, developed by the National Vaccine & Serum Institute, a R&D centre of Sinopharm's bioscience subsidiary the China National Biotec Group (CNBG), got approval from the National Medical Products Administration on Friday, the CNBG said on its official Weibo account on Saturday, Xinhua reported.

COVID-19 Vaccination in India: Issues and Challenges
India’s COVID-19 vaccination program has been launched. It currently uses the vaccines Covishield and Covaxin. There are some issues and challenges that need to be overcome in order to vaccinate all Indians.

‘The COVID-19 vaccine is based on the structural features of the receptor binding domain (RBD) on the virus' spike protein (S-protein).’

It uses genetic engineering to grow harmless copies of the virus S-protein to induce neutralising antibodies.

The company said that recombinant vaccine technology is mature and suitable for large-scale production. The production does not require facilities with high biosafety levels since the process does not involve live viruses.

The recombinant vaccine is the company's third Covid-19 vaccine. Last December, an inactivated vaccine developed by the Beijing Biological Products Institute Co., Ltd. under CNBG became the first Chinese Covid-19 vaccine to have conditional marketing authorisation.

Shocking Imbalance of Covid-19 Vax Distribution Between Rich and Poor Countries
WHO Director General Tedros Adhanom Ghebreyesus warned that the world was facing a catastrophic moral failure over vaccine inequality earlier this year. Now, he criticizes over the distribution of coronavirus vaccines between rich and poor countries, as a shocking imbalance.

In February, another inactivated vaccine from the Wuhan Institute of Biological Products, a CNBG affiliate, was allowed to enter the market on a conditional basis.

More than 161.12 million doses of Covid-19 vaccines had been administered across China as of Friday, the National Health Commission said on Saturday.

COVID-19 Update: Effective Shot Against Mutations can be Produced
The COVID-19 vaccine technology platform for Covaxin and Covishield, can develop effective effective vaccines against mutations.

Source-IANS

Maharashtra COVID-19 Tally Crosses 33 Lakh
In Maharashtra COVID-19 tally has crossed the 33-lakh mark, while the death toll in Mumbai Metropolitan Region (MMR) zoomed past the 21,000-mark with over 30 lakh people under quarantine, reported sources.